+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

China Indapamide Market 2020-2026

  • PDF Icon


  • August 2020
  • Region: China
  • Orion Market Research Private Limited
  • ID: 5148040
China Indapamide Market Size, Share & Trends Analysis Report by product (1.25 mg and 2.5 mg), By Application (High Blood Pressure, Heart Failure, and Others), and Forecast 2020-2026.

China indapamide market is estimated to grow at a CAGR of around 4.1% during the forecast period. The market is mainly driven due to growing various heart-related diseases and other diseases in the country. Lack of physical activity, obese population, alcohol consumption, unhealthy diet, and smoking are some major factors leading to the rising number of incidences of these conditions. The rising aging population may further increase the risk of hypertension in China. With the age, arteries get stiffer and thereby blood pressure goes up. Apart from the aging population, the condition has been shown to increase among adults in the country. As per the findings by the researchers at Yale and the Chinese National Center for Cardiovascular Disease published in October 2017, over one-third of adults in China are suffering from high blood pressure. Hypertension raised the risk of severe health problems, such as heart attack and stroke. The use of indapamide supports to reduce the blood pressure and the risk of having other severe condition among patients.

China indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg indapamide held a significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

The companies which are contributing to the growth of the China indapamide market include Glenmark Pharmaceuticals Ltd, Shandong Yinfeida Pharmaceutical Co., Ltd., Suzhou Lixin Pharmaceutical Co., Ltd., Merck KGaA, Sanofi S.A., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.

Research Methodology:

The market study of the China indapamide market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for indapamide market players, pharmaceutical companies, drug manufacturers, government organizations, regulatory bodies, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis on market size, products offered by the companies, and future market opportunities. The report will serve as a source for 360-degree analysis of the market delivering insights into the market for making better business decisions.

Market Segmentation:

1. China Indapamide Market Research and Analysis by Product
2. China Indapamide Market Research and Analysis by Application

The Report Covers:
  • Comprehensive research methodology of the China indapamide market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the China indapamide market.
  • Insights about market determinants which are stimulating the China indapamide market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints/Restraints
4.3. Opportunities
5. Market Segmentation
5.1. China Indapamide Market by Product
5.1.1. 1.25 MG
5.1.2. 2.5 MG
5.2. China Indapamide Market by Application
5.2.1. High Blood Pressure
5.2.2. Heart Failure
5.2.3. Others
6. Company Profiles
6.1. ANI Pharmaceuticals, Inc.
6.2. Glenmark Pharmaceuticals Ltd.
6.3. Merck KGaA
6.4. Sandoz International GmbH
6.5. Sanofi S.A.
6.6. Shandong Yinfeida Pharmaceutical Co., Ltd.
6.7. Supra Chemicals
6.8. Suzhou Lixin Pharmaceutical Co., Ltd.
6.9. Taj Pharmaceuticals Ltd.
6.10. Torrent Pharmaceuticals Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ANI Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Merck KGaA
  • Sandoz International GmbH
  • Sanofi S.A.
  • Shandong Yinfeida Pharmaceutical Co., Ltd.
  • Supra Chemicals
  • Suzhou Lixin Pharmaceutical Co., Ltd.
  • Taj Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.